Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 10/20 | 0.76 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30608416 | 1.00 | HTR2B (0.76) | HTR2BGPR35HTR1DHTR7HTR3A | |
| SCHEMBL1534272 | 1.00 | HTR2B (0.76) | HTR2BGPR35HTR1DHTR7HTR3A | |
| SCHEMBL26117247 | 1.00 | HTR2B (0.76) | HTR2BGPR35HTR1DHTR7HTR3A | |
| SCHEMBL11050644 | 0.98 | HTR2B (0.74) | HTR2BGPR35HTR1DHTR7HTR3A | |
| SCHEMBL15602812 | 0.88 | HTR2B (0.59) | HTR2BGPR35HTR1DHTR7HTR3A | |
| SCHEMBL15602915 | 0.88 | HTR2B (0.59) | HTR2BGPR35HTR1DHTR7HTR3A | |
| Pulicatins G SCHEMBL12469063 | 0.86 | HTR2B (1.00) | HTR2BGPR35HTR1DHTR7HTR3A | |
| SCHEMBL11925403 | 0.86 | HTR2B (0.74) | HTR2BGPR35HTR1DHTR7HTR3A | |
| SCHEMBL3993242 | 0.86 | HTR2B (0.74) | HTR2BGPR35HTR1DHTR7HTR3A | |
| SCHEMBL3993320 | 0.86 | HTR2B (0.74) | HTR2BGPR35HTR1DHTR7HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197388-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | EMPRESS THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| WO-2023192388-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192388-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2023-10-05 | — | — | WO | disclosed |
| US-9346799-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICALS AG (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2016-05-05 | — | — | US | disclosed |
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2015-01-29 | — | — | US | disclosed |
| US-8901293-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2014-12-02 | — | — | US | disclosed |
| EP-2484680-B1 | Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2013-06-26 | — | — | EP | disclosed |
| EP-2484680-A1 | Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors | Basilea Pharmaceutica AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| US-20120184586-A1 | DESFERRITHIOCIN POLYETHER ANALOGUES AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-1965798-B1 | USEFUL MONOBACTAM ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2011-10-19 | — | — | EP | disclosed |
| EP-2308874-A1 | Useful beta-lactamase inhibitors | Basilea Pharmaceutica AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100137346-A1 | DESFERRITHIOCIN ANALOGUE ACTINIDE DECORPORATION AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2010-03-04 | — | — | US | disclosed |
| EP-2101764-A2 | DESFERRITHIOCIN ANALOGUE ACTINIDE DECORPORATION AGENTS | UNIVERSITY OF FLORIDA (US) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008130395-A2 | DESFERRITHIOCIN ANALOGUE ACTINIDE DECORPORATION AGENTS | UNIVERSITY OF FLORIDA (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-1965798-A2 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | Basilea Pharmaceutica AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007065288-A2 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | HTR2B 4705/4885GPR35 4132/4885HTR1D 4829/4885 |
| US-20120184586-A1 | DESFERRITHIOCIN POLYETHER ANALOGUES AND USES THEREOF | TFRC, FTH1, TTPA | HTR2B 4643/4885GPR35 4414/4885HTR1D 4749/4885 |
| US-20250197388-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | SI, VIP, APC | HTR2B 2431/4885GPR35 1704/4885HTR1D 3353/4885 |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | HTR2B 4705/4885GPR35 4132/4885HTR1D 4829/4885 |
| US-20100137346-A1 | DESFERRITHIOCIN ANALOGUE ACTINIDE DECORPORATION AGENTS | TFRC, SLC40A1, FIBP | HTR2B 3077/4885GPR35 4449/4885HTR1D 3258/4885 |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | MGAM, MGAM2, B2M | HTR2B 4771/4885GPR35 4157/4885HTR1D 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.